Norden Group LLC Has $689,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Norden Group LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 9.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,932 shares of the biopharmaceutical company’s stock after selling 2,535 shares during the quarter. Norden Group LLC’s holdings in Pfizer were worth $689,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in PFE. Arcadia Investment Management Corp MI raised its stake in shares of Pfizer by 9.5% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 11,545 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 1,000 shares during the period. Innova Wealth Partners acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $208,000. Busey Trust CO increased its position in shares of Pfizer by 1.1% in the third quarter. Busey Trust CO now owns 668,948 shares of the biopharmaceutical company’s stock valued at $22,189,000 after acquiring an additional 7,527 shares during the last quarter. Toews Corp ADV acquired a new stake in shares of Pfizer in the third quarter valued at about $813,000. Finally, Accurate Wealth Management LLC increased its position in shares of Pfizer by 7.5% in the third quarter. Accurate Wealth Management LLC now owns 35,396 shares of the biopharmaceutical company’s stock valued at $1,159,000 after acquiring an additional 2,467 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Trading Down 0.1 %

Shares of NYSE:PFE opened at $25.61 on Wednesday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The stock has a market cap of $145.02 billion, a PE ratio of 71.14, a P/E/G ratio of 1.16 and a beta of 0.61. The business has a 50 day moving average of $26.88 and a 200-day moving average of $28.26. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the company posted $1.14 earnings per share. The business’s revenue was down 41.3% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.56%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.